Serina using $5M to develop SER-252 for advanced Parkinson’s
Serina Therapeutics will use $5 million in new funding to further develop SER-252 (POZ-apomorphine) as a treatment for advanced Parkinson’s disease, with a Phase 1 clinical study now expected by the end of the year. The company secured the financing from shareholders to support clinical testing of SER-252,…